Reports for APOTEX INC
Company Name
APOTEX INC
Totals |
||
Shortage reports |
3356 |
|
| Actual shortage: | 218 (6%) | |
| Anticipated shortage: | 0 (0%) | |
| Avoided shortage: | 10 (0%) | |
| Resolved: | 3128 (93%) | |
Discontinuation Reports |
359 |
|
| To be discontinued: | 24 (7%) | |
| Discontinued: | 335 (93%) | |
| Reversed: | 0 (0%) | |
Late reports |
144 (4%) |
|
Overdue reports |
62 (26%) |
|
Shortage reports
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| APO-LORAZEPAM | 2MG | TABLET | Resolved | 2021-12-01 | 2021-12-20 | 150252 |
| APO-LORAZEPAM | 2MG | TABLET | Resolved | 2022-04-01 | 2022-05-13 | 157698 |
| APO-LOSARTAN | 50MG | TABLET | Resolved | 2017-03-12 | 2017-03-16 | 722 |
| APO-LOSARTAN | 50MG | TABLET | Actual shortage | 2018-05-01 | 2019-03-15 | 47652 |
| APO-LOSARTAN | 100MG | TABLET | Actual shortage | 2018-05-15 | 2019-04-11 | 49490 |
| APO-LOSARTAN | 25MG | TABLET | Actual shortage | 2018-07-11 | 2019-03-15 | 55284 |
| APO-LOSARTAN | 100MG | TABLET | Actual shortage | 2018-12-27 | 2019-04-17 | 70523 |
| APO-LOSARTAN/HCTZ | 25MG 100MG | TABLET | Resolved | 2018-03-27 | 2018-09-11 | 44105 |
| APO-LOSARTAN/HCTZ | 25MG 100MG | TABLET | Resolved | 2018-05-15 | 2018-09-15 | 49493 |
| APO-LOSARTAN/HCTZ | 12.5MG 50MG | TABLET | Resolved | 2018-07-15 | 2018-09-15 | 55807 |
| APO-LOSARTAN/HCTZ | 12.5MG 100MG | TABLET | Resolved | 2017-10-24 | 2018-09-11 | 26827 |
| APO-LOSARTAN/HCTZ | 12.5MG 50MG | TABLET | Resolved | 2018-02-13 | 2018-09-10 | 39656 |
| APO-LOXAPINE | 5MG | TABLET | Actual shortage | 2017-08-13 | 2017-10-05 | 19075 |
| APO-LOXAPINE | 10MG | TABLET | Actual shortage | 2017-08-13 | 2017-10-05 | 19078 |
| APO-LOXAPINE | 25MG | TABLET | Actual shortage | 2017-08-13 | 2017-10-05 | 19081 |
| APO-LOXAPINE | 50MG | TABLET | Actual shortage | 2017-08-13 | 2017-10-05 | 19084 |
| APO-MELOXICAM | 15MG | TABLET | Resolved | 2017-03-10 | 2017-07-13 | 378 |
| APO-MELOXICAM | 1.5G | SUSPENSION | Resolved | 2017-03-11 | 2019-11-25 | 586 |
| APO-MELOXICAM | 1.5G | SUSPENSION | Resolved | 2017-03-11 | 2018-05-02 | 589 |
| APO-MELOXICAM | 7.5MG | TABLET | Resolved | 2017-05-04 | 2017-10-05 | 8871 |
Discontinuation reports
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| APO-BISACODYL | 5MG | TABLET (DELAYED-RELEASE) | Discontinued | 2018-09-07 | 2018-09-15 | 60288 |
| APO-BOSENTAN | 62.5MG | TABLET | Discontinued | 2019-01-04 | 2019-01-04 | 71339 |
| APO-BOSENTAN | 125.0MG | TABLET | Discontinued | 2019-01-04 | 2019-01-04 | 71342 |
| APO-BOSENTAN | 125.0MG | TABLET | Discontinued | 2018-09-07 | 2018-10-31 | 60291 |
| APO-BRIMONIDINE | 0.2% | SOLUTION | Discontinued | 2020-11-16 | 2020-11-16 | 128438 |
| APO-BRIMONIDINE | 0.2% | SOLUTION | To be discontinued | 2018-09-07 | 2018-09-07 | 60294 |
| APO-BRIMONIDINE | 0.2% | SOLUTION | Discontinued | 2018-09-07 | 2018-12-28 | 60301 |
| APO-BROMAZEPAM | 1.5MG | TABLET | To be discontinued | 2018-09-07 | 2018-09-07 | 60304 |
| APO-BROMAZEPAM | 3MG | TABLET | Discontinued | 2018-09-07 | 2019-06-12 | 60307 |
| APO-BROMAZEPAM | 6MG | TABLET | Discontinued | 2018-09-07 | 2018-10-19 | 60310 |
| APO-CANDESARTAN | 16MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60313 |
| APO-CANDESARTAN | 16MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60316 |
| APO-CANDESARTAN | 32MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60328 |
| APO-CANDESARTAN | 8MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60325 |
| APO-CANDESARTAN | 8MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60322 |
| APO-CANDESARTAN | 4MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60319 |
| APO-CANDESARTAN/HCTZ | 12.5MG 16.0MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60335 |
| APO-CANDESARTAN/HCTZ | 12.5MG 16.0MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60331 |
| APO-CANDESARTAN/HCTZ | 25MG 32MG | TABLET | Discontinued | 2018-02-26 | 2018-05-03 | 41011 |
| APO-CANDESARTAN/HCTZ | 12.5MG 32MG | TABLET | Discontinued | 2018-02-26 | 2018-02-26 | 41020 |